NCT03875092View on ClinicalTrials.gov

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

PHASE3CompletedINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

April 21, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

September 14, 2023

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Carboplatin

IV infusion Carboplatin dose should not exceed 900 mg.

DRUG

Saline placebo for pembrolizumab

IV infusion

Trial Locations (1)

200032

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03875092 - A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | Biotech Hunter | Biotech Hunter